Biohaven Ltd. Costs and Expenses
Biohaven Ltd. (BHVN) reported Costs and Expenses of $124.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-10
- Biohaven Ltd. costs and expenses for the quarter ending 2026-06-30 was $124.90M, a 41.00% decline year-over-year.
- Biohaven Ltd. costs and expenses for the quarter ending 2026-03-31 was $130.43M, a 41.13% decline year-over-year.
- Biohaven Ltd. costs and expenses for the quarter ending 2025-12-31 was $142.73M, a 24.85% decline year-over-year.
- Biohaven Ltd. costs and expenses for the quarter ending 2025-09-30 was $169.38M, a 4.93% decline year-over-year.
- Biohaven Ltd. costs and expenses for fiscal 2025 was $745.38M, a 15.79% decline from fiscal 2024.
- Biohaven Ltd. costs and expenses for fiscal 2024 was $885.11M, a 102.98% increase from fiscal 2023.
- Biohaven Ltd. costs and expenses for fiscal 2023 was $436.05M, a 23.22% decline from fiscal 2022.
- Biohaven Ltd. costs and expenses for fiscal 2022 was $567.93M, a 159.45% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $124.90M 10-Q · filed 2026-08-10 | $255.33M 10-Q · filed 2026-08-10 | $398.06M derived: sum of 3 quarters · filed 2026-08-10 | $567.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $130.43M 10-Q · filed 2026-05-04 | $273.16M derived: sum of 2 quarters · filed 2026-05-04 | $442.54M derived: sum of 3 quarters · filed 2026-05-04 | $654.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $142.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $312.12M derived: sum of 2 quarters · filed 2026-03-02 | $523.82M derived: sum of 3 quarters · filed 2026-08-10 | $745.38M 10-K · filed 2026-03-02 |
| 2025-09-30 | $169.38M 10-Q · filed 2025-11-10 | $381.08M derived: sum of 2 quarters · filed 2026-08-10 | $602.64M 10-Q · filed 2025-11-10 | $792.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $211.70M 10-Q · filed 2026-08-10 | $433.26M 10-Q · filed 2026-08-10 | $623.19M derived: sum of 3 quarters · filed 2026-08-10 | $801.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $221.56M 10-Q · filed 2026-05-04 | $411.49M derived: sum of 2 quarters · filed 2026-05-04 | $589.66M derived: sum of 3 quarters · filed 2026-05-04 | $923.43M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $189.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $368.10M derived: sum of 2 quarters · filed 2026-03-02 | $701.87M derived: sum of 3 quarters · filed 2026-03-02 | $885.11M 10-K · filed 2026-03-02 |
| 2024-09-30 | $178.17M 10-Q · filed 2025-11-10 | $511.94M derived: sum of 2 quarters · filed 2025-11-10 | $695.18M 10-Q · filed 2025-11-10 | $848.89M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $333.77M 10-Q · filed 2025-08-11 | $517.01M 10-Q · filed 2025-08-11 | $670.72M derived: sum of 3 quarters · filed 2026-03-02 | $781.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $183.24M 10-Q · filed 2025-05-12 | $336.95M derived: sum of 2 quarters · filed 2026-03-02 | $447.50M derived: sum of 3 quarters · filed 2026-03-02 | $541.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $153.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $264.26M derived: sum of 2 quarters · filed 2026-03-02 | $358.27M derived: sum of 3 quarters · filed 2026-03-02 | $436.05M 10-K · filed 2026-03-02 |
| 2023-09-30 | $110.55M 10-Q · filed 2024-11-12 | $204.56M derived: sum of 2 quarters · filed 2024-11-12 | $282.34M 10-Q · filed 2024-11-12 | $495.75M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $94.01M 10-Q · filed 2024-08-09 | $171.79M 10-Q · filed 2024-08-09 | $385.20M derived: sum of 3 quarters · filed 2025-03-03 | $452.84M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $77.78M 10-Q · filed 2024-05-09 | $291.19M derived: sum of 2 quarters · filed 2025-03-03 | $358.83M derived: sum of 3 quarters · filed 2025-03-03 | $555.94M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $213.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $281.05M derived: sum of 2 quarters · filed 2025-03-03 | $478.16M derived: sum of 3 quarters · filed 2025-03-03 | $567.93M 10-K · filed 2025-03-03 |
| 2022-09-30 | $67.64M 10-Q · filed 2023-11-14 | $264.75M derived: sum of 2 quarters · filed 2023-11-14 | $354.52M 10-Q · filed 2023-11-14 | $405.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $197.11M 10-Q · filed 2023-07-31 | $286.88M 10-Q · filed 2023-07-31 | $337.77M derived: sum of 3 quarters · filed 2024-02-29 | $393.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $89.77M 10-Q · filed 2023-05-12 | $140.66M derived: sum of 2 quarters · filed 2024-02-29 | $196.15M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $50.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $106.38M derived: sum of 2 quarters · filed 2024-02-29 | $218.90M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $55.49M 10-Q · filed 2022-11-09 | $168.02M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |